BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8536345)

  • 1. Synthesis and antitumor activity of novel dolastatin 10 analogs.
    Miyazaki K; Kobayashi M; Natsume T; Gondo M; Mikami T; Sakakibara K; Tsukagoshi S
    Chem Pharm Bull (Tokyo); 1995 Oct; 43(10):1706-18. PubMed ID: 8536345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and cytostatic properties of structure-simplified analogs of dolastatin 15.
    Hu MK; Huang WS
    J Pept Res; 1999 Dec; 54(6):460-7. PubMed ID: 10604591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
    Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Durkin KP; Boyd MR; Bai R; Hamel E; Schmidt JM; Chapuis JC
    Anticancer Drug Des; 1995 Oct; 10(7):529-44. PubMed ID: 7495477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and X-ray crystal structure of the dolabellaauricularia peptide dolastatin 18.
    Pettit GR; Hogan F; Herald DL
    J Org Chem; 2004 Jun; 69(12):4019-22. PubMed ID: 15176826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity.
    Bai R; Roach MC; Jayaram SK; Barkoczy J; Pettit GR; Ludueña RF; Hamel E
    Biochem Pharmacol; 1993 Apr; 45(7):1503-15. PubMed ID: 8471072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antineoplastic agents 365. Dolastatin 10 SAR probes.
    Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Boyd MR; Hamel E; Pettit RK; Hogan F; Bai R; Chapuis JC; McAllister SC; Schmidt JM
    Anticancer Drug Des; 1998 Jun; 13(4):243-77. PubMed ID: 9627667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of novel dolastatin 10 derivatives for versatile conjugations.
    Yokosaka S; Izawa A; Sakai C; Sakurada E; Morita Y; Nishio Y
    Bioorg Med Chem; 2018 May; 26(8):1643-1652. PubMed ID: 29454703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation and structure of the human cancer cell growth inhibitory cyclodepsipeptide dolastatin 16.
    Pettit GR; Xu JP; Hogan F; Williams MD; Doubek DL; Schmidt JM; Cerny RL; Boyd MR
    J Nat Prod; 1997 Aug; 60(8):752-4. PubMed ID: 9287413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of Dolastatin 15 mimetic peptoids.
    Schmitt J; Bernd M; Kutscher B; Kessler H
    Bioorg Med Chem Lett; 1998 Feb; 8(4):385-8. PubMed ID: 9871690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15.
    Poncet J; Busquet M; Roux F; Pierré A; Atassi G; Jouin P
    J Med Chem; 1998 Apr; 41(9):1524-30. PubMed ID: 9554885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antiproliferative activity of a cyclic analog of dolastatin 10.
    Poncet J; Hortala L; Busquet M; Guéritte-Voegelein F; Thoret S; Pierré A; Atassi G; Jouin P
    Bioorg Med Chem Lett; 1998 Oct; 8(20):2855-8. PubMed ID: 9873636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor agents. V. Synthesis and antileukemic activity of E-ring-modified (RS)-camptothecin analogues.
    Ejima A; Terasawa H; Sugimori M; Ohsuki S; Matsumoto K; Kawato Y; Yasuoka M; Tagawa H
    Chem Pharm Bull (Tokyo); 1992 Mar; 40(3):683-8. PubMed ID: 1611680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Evaluation of Dolastatin 10 Analogues Containing Heteroatoms on the Amino Acid Side Chains.
    Dugal-Tessier J; Barnscher SD; Kanai A; Mendelsohn BA
    J Nat Prod; 2017 Sep; 80(9):2484-2491. PubMed ID: 28885014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
    Bai R; Friedman SJ; Pettit GR; Hamel E
    Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrimidoacridine derivatives as potential antitumor agents.
    Antonini I; Cola D; Martelli S; Cholody WM; Konopa J
    Farmaco; 1992; 47(7-8):1035-46. PubMed ID: 1445611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1.
    Luesch H; Moore RE; Paul VJ; Mooberry SL; Corbett TH
    J Nat Prod; 2001 Jul; 64(7):907-10. PubMed ID: 11473421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lyngbyastatin 1 and Ibu-epilyngbyastatin 1: synthesis, stereochemistry, and NMR line broadening.
    Bai R; Bates RB; Hamel E; Moore RE; Nakkiew P; Pettit GR; Sufi BA
    J Nat Prod; 2002 Dec; 65(12):1824-9. PubMed ID: 12502322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium Symploca sp. VP452.
    Luesch H; Yoshida WY; Moore RE; Paul VJ; Mooberry SL; Corbett TH
    J Nat Prod; 2002 Jan; 65(1):16-20. PubMed ID: 11809057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dolastatins, a family of promising antineoplastic agents.
    Poncet J
    Curr Pharm Des; 1999 Mar; 5(3):139-62. PubMed ID: 10066887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola cyanobacterial assemblages.
    Harrigan GG; Yoshida WY; Moore RE; Nagle DG; Park PU; Biggs J; Paul VJ; Mooberry SL; Corbett TH; Valeriote FA
    J Nat Prod; 1998 Oct; 61(10):1221-5. PubMed ID: 9784156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.